Athersys is a clinical-stage biopharmaceutical company with a growing pipeline of "potential best-in-class therapeutics" it hopes will provide some answers to issues such as heart attacks, obesity and cognitive disorders. Currently, the Cleveland-based company is continuing its enrollments in safety and efficacy trials of its adult stem-cell therapy MultiStem, for heart attack patients and for those who run the risk of rejecting bone marrow transplants. MulitStem is a biologic product manufactured from human stem cells obtained from adult bone marrow. However, Athersys is also exploring other avenues of development including medicines for the treatment of metabolic and central nervous system. The company was founded in 1995.